Cerulea Clinical Trials

Science and Research


Safety and efficacy of NP1-001 tablets for retinitis pigmentosa associated with Usher syndrome. This study will examine the safety and potential impact of a new treatment in slowing down retinal changes associated with retinitis pigmentosa (RP) in people with Usher syndrome.


This study will explore the safety and potential effect of NPI-001 therapy in people with RP associated with Usher syndrome. There will be a treatment group and a placebo group being compared over time.

The study will look at retinal sensitivity assessed by microperimetry from baseline, as well as a range of features across various retinal imaging modalities.

  • Principal Investigator
Dr Jonathan Ruddle

Learn more

View this study at ClinicalTrials.gov

This international database listing provides more detailed information about this study.